Suggested remit: To appraise the clinical and cost effectiveness of tanezumab within its marketing authorisation for treating moderate to severe chronic pain caused by osteoarthritis.
Status In progress
Process STA 2018
ID number 1603

Provisional Schedule

Committee meeting: 1 06 July 2021
Expected publication 15 September 2021

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Key events during the development of the guidance:

Date Update
26 October 2020 Invitation to participate
26 October 2020 In progress. STA
03 August 2020 - 01 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance